by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION To examine the burden and clusters of multimorbidity in association with mild cognitive impairment (MCI), dementia, and Alzheimer’s disease (AD)-related plasma biomarkers among older adults. METHODS This population-based study included 5432...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION White matter hyperintensities (WMH) may promote clinical Alzheimer’s disease (AD) disparities between Black American (BA) and non-Hispanic White (nHW) populations. Using a novel measurement, unhealthy white matter connectivity (UWMC), we...
by Clinical Neuropsychologist Online | Thursday, March 14, 2024 | Dementia
Abstract INTRODUCTION Dementia risk may be elevated in socioeconomically disadvantaged neighborhoods. Reasons for this remain unclear, and this elevation has yet to be shown at a national population level. METHODS We tested whether dementia was more prevalent in...
by Clinical Neuropsychologist Online | Thursday, March 14, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | March 14, 2024 Wiley: Alzheimer’s & Dementia: Table...
by Clinical Neuropsychologist Online | Thursday, March 14, 2024 | Dementia
Abstract Prior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset...
